455 related articles for article (PubMed ID: 31612116)
1. Mechanisms of Vasculogenic Mimicry in Ovarian Cancer.
Ayala-Domínguez L; Olmedo-Nieva L; Muñoz-Bello JO; Contreras-Paredes A; Manzo-Merino J; Martínez-Ramírez I; Lizano M
Front Oncol; 2019; 9():998. PubMed ID: 31612116
[TBL] [Abstract][Full Text] [Related]
2. An Overview of Vasculogenic Mimicry in Breast Cancer.
Andonegui-Elguera MA; Alfaro-Mora Y; Cáceres-Gutiérrez R; Caro-Sánchez CHS; Herrera LA; Díaz-Chávez J
Front Oncol; 2020; 10():220. PubMed ID: 32175277
[TBL] [Abstract][Full Text] [Related]
3. cRGD-functionalized nanoparticles for combination therapy of anti-endothelium dependent vessels and anti-vasculogenic mimicry to inhibit the proliferation of ovarian cancer.
Wang Y; Tong L; Wang J; Luo J; Tang J; Zhong L; Xiao Q; Niu W; Li J; Zhu J; Chen H; Li X; Wang Y
Acta Biomater; 2019 Aug; 94():495-504. PubMed ID: 31252171
[TBL] [Abstract][Full Text] [Related]
4. Angiogenesis and vasculogenic mimicry as therapeutic targets in ovarian cancer.
Lim D; Do Y; Kwon BS; Chang W; Lee MS; Kim J; Cho JG
BMB Rep; 2020 Jun; 53(6):291-298. PubMed ID: 32438972
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of vasculogenic mimicry in hypoxic tumor microenvironments.
Wei X; Chen Y; Jiang X; Peng M; Liu Y; Mo Y; Ren D; Hua Y; Yu B; Zhou Y; Liao Q; Wang H; Xiang B; Zhou M; Li X; Li G; Li Y; Xiong W; Zeng Z
Mol Cancer; 2021 Jan; 20(1):7. PubMed ID: 33397409
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy checkpoints in ovarian cancer vasculogenic mimicry: Tumor immune microenvironments, and drugs.
Hu H; Ma T; Liu N; Hong H; Yu L; Lyu D; Meng X; Wang B; Jiang X
Int Immunopharmacol; 2022 Oct; 111():109116. PubMed ID: 35969899
[TBL] [Abstract][Full Text] [Related]
7. Functional significance of VEGF-a in human ovarian carcinoma: role in vasculogenic mimicry.
Wang JY; Sun T; Zhao XL; Zhang SW; Zhang DF; Gu Q; Wang XH; Zhao N; Qie S; Sun BC
Cancer Biol Ther; 2008 May; 7(5):758-66. PubMed ID: 18376140
[TBL] [Abstract][Full Text] [Related]
8. Molecular mechanisms of Thrombospondin-2 modulates tumor vasculogenic mimicry by PI3K/AKT/mTOR signaling pathway.
Huang J; Wang C; Hou Y; Tian Y; Li Y; Zhang H; Zhang L; Li W
Biomed Pharmacother; 2023 Nov; 167():115455. PubMed ID: 37696083
[TBL] [Abstract][Full Text] [Related]
9. Glioblastoma vasculogenic mimicry: signaling pathways progression and potential anti-angiogenesis targets.
Mao JM; Liu J; Guo G; Mao XG; Li CX
Biomark Res; 2015; 3():8. PubMed ID: 26085929
[TBL] [Abstract][Full Text] [Related]
10. Vasculogenic mimicry is associated with poor survival in patients with mesothelial sarcomas and alveolar rhabdomyosarcomas.
Sun B; Zhang S; Zhao X; Zhang W; Hao X
Int J Oncol; 2004 Dec; 25(6):1609-14. PubMed ID: 15547697
[TBL] [Abstract][Full Text] [Related]
11. cRGD inhibits vasculogenic mimicry formation by down-regulating uPA expression and reducing EMT in ovarian cancer.
Tang J; Wang J; Fan L; Li X; Liu N; Luo W; Wang J; Wang Y; Wang Y
Oncotarget; 2016 Apr; 7(17):24050-62. PubMed ID: 26992227
[TBL] [Abstract][Full Text] [Related]
12. Downregulation of transgelin blocks interleukin-8 utilization and suppresses vasculogenic mimicry in breast cancer cells.
Aikins AR; Kim M; Raymundo B; Kim CW
Exp Biol Med (Maywood); 2017 Mar; 242(6):573-583. PubMed ID: 28058861
[TBL] [Abstract][Full Text] [Related]
13. Cancer Stem Cells and Its Role in Angiogenesis and Vasculogenic Mimicry in Gastrointestinal Cancers.
Lizárraga-Verdugo E; Avendaño-Félix M; Bermúdez M; Ramos-Payán R; Pérez-Plasencia C; Aguilar-Medina M
Front Oncol; 2020; 10():413. PubMed ID: 32296643
[TBL] [Abstract][Full Text] [Related]
14. CD36 promotes vasculogenic mimicry in melanoma by mediating adhesion to the extracellular matrix.
Martini C; DeNichilo M; King DP; Cockshell MP; Ebert B; Dale B; Ebert LM; Woods A; Bonder CS
BMC Cancer; 2021 Jul; 21(1):765. PubMed ID: 34215227
[TBL] [Abstract][Full Text] [Related]
15. Signaling pathways in tumor vasculogenic mimicry.
Vartanian AA
Biochemistry (Mosc); 2012 Sep; 77(9):1044-55. PubMed ID: 23157265
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-27b functions as a new inhibitor of ovarian cancer-mediated vasculogenic mimicry through suppression of
Liu W; Lv C; Zhang B; Zhou Q; Cao Z
RNA; 2017 Jul; 23(7):1019-1027. PubMed ID: 28396577
[TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor/heat shock protein 27 pathway regulates vasculogenic mimicry activity of breast cancer stem/progenitor cells.
Lee CH; Wu YT; Hsieh HC; Yu Y; Yu AL; Chang WW
Biochimie; 2014 Sep; 104():117-26. PubMed ID: 24950183
[TBL] [Abstract][Full Text] [Related]
18. The role of miR-200a in vasculogenic mimicry and its clinical significance in ovarian cancer.
Sun Q; Zou X; Zhang T; Shen J; Yin Y; Xiang J
Gynecol Oncol; 2014 Mar; 132(3):730-8. PubMed ID: 24503464
[TBL] [Abstract][Full Text] [Related]
19. Regulation Networks Driving Vasculogenic Mimicry in Solid Tumors.
Hernández de la Cruz ON; López-González JS; García-Vázquez R; Salinas-Vera YM; Muñiz-Lino MA; Aguilar-Cazares D; López-Camarillo C; Carlos-Reyes Á
Front Oncol; 2019; 9():1419. PubMed ID: 31993365
[TBL] [Abstract][Full Text] [Related]
20. Epithelial-to-endothelial transition and cancer stem cells: two cornerstones of vasculogenic mimicry in malignant tumors.
Sun B; Zhang D; Zhao N; Zhao X
Oncotarget; 2017 May; 8(18):30502-30510. PubMed ID: 27034014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
